Abzena and Telix sign licence agreement for Abzena’s Prostate-Specific Membrane Antigen Antibodies
Under the terms of the Agreement, Abzena has granted Telix an exclusive worldwide, royalty bearing, sub-licensable licence to its prostate-specific membrane antigen (‘PSMA’) antibodies in the field of radio-immunoconjugation. The PSMA antibodies were created using Abzena’s Composite Human Antibody™ technology.Read More
Technologies and Solutions
Abzena provides proprietary technologies and complementary solutions to organisations involved in the development of biopharmaceutical products.
Latest News and Events
Abzena presents its latest research and exhibits at events all over the world.
Find out where we are next and our latest news below.
Novel antibodies against a ground-breaking new target for the treatment of Cardiovascular Fibrosis developed by Enleofen Bio, with support from Abzena, featured in ‘Nature’ article
Antibody Engineering and Therapeutics
San Diego, CA, USA
10 December 2017
Abzena and UGA Biopharma Partner to Develop a Cell Line Expressing a Biosimilar Therapeutic for Multiple Sclerosis
QEII Centre, Westminster, London, UK
14 December 2017
Resources and Downloads
Find our latest videos, brochures and fact sheets in our resources section.
Download our Brochure
Technology & Solutions BrochureDownload File
Modulation of drug-linker design to enhance in vivo potency of homogeneous antibody-drug conjugates
Antibody-drug conjugates (ADCs) are a promising class of anticancer agents which have undergone substantial development…Read More
Manufacturing & Cell Line Development at Abzena
Abzena has extensive experience in cGMP and non-GMP production for recombinant proteins, antibodies and conjugates…